High baseline LRRFIP1 induction in glioblastoma multiforme (GBM) is linked with improved activity to teniposide type II topoisomerase inhibitory agent, LRRFIP1 shRNA lentivirus as prevention strategy for Deep vein thrombosis (DVT), LRRFIP1 induces IFN‐β and inhibits HCV infection in hepatocytes, LRRFIP1 silencing backs the epithelial‐mesenchymal transition (EMT) through inhibitory response of Wnt/β‐catenin. Here, LRRFIP1 is linked to glioblastoma.